The oral OMNI-EGFR inhibitor earned fast track status for advanced EGFR C797S–positive non–small cell lung cancer that progressed on a third-generation EGFR TKI.
News|Videos|June 25, 2024
Subcutaneous Amivantamab vs Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory EGFR-Mutated, Advanced Non-Small Cell Lung Cancer (NSCLC): Primary Results, Including Overall Survival (OS), From the Global, Phase 3, Randomized Controlled PALOMA-3 Trial
Author(s)Natasha B Leighl, MD, BSc, MMSc
Dr. Natasha Leighl presents the primary results of the phase 3, randomized controlled PALOMA-3 (NCT05388669) trial assessing the overall survival and non-inferiority of subcutaneous amivantamab compared to intravenous amivantamab, in combination with lazertinib, in patients with refractory EGFR-mutated, advanced non-small cell lung cancer.
Advertisement
Newsletter
Stay up to date on the most recent and practice-changing oncology data
SubscribeAdvertisement
Related to this article
T-DXd improved PFS in the phase 3 DESTINY-Lung04 trial for first-line HER2-mutant NSCLC.
Phase 3 eVOLVE-Lung02 Trial of First-Line Volrustomig Is Discontinued in First-Line Metastatic NSCLC
The phase 3 eVOLVE-Lung02 trial is being discontinued after its IDMC found volrustomig plus chemotherapy unlikely to meet its dual primary end points.
The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Zipalertinib plus chemotherapy produced a statistically significant, clinically meaningful PFS improvement vs chemotherapy alone at a planned interim analysis.
Daniel Boiarsky, MD, and William Phillips, MD, discuss findings from studies that they presented during the OncLive National Fellows Forum: Lung Cancer.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
Advertisement
Advertisement
Trending on OncLive
1
Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma
2
ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC
3
mRNA Vaccines May Help Increase Long-Term Disease Control in PDAC
4
FDA Grants Fast Track Designation to PLN-101095 Plus Pembrolizumab in Solid Tumors
5